Cat. #160880
MLL-AF9-miR-139 knock out cell line
Cat. #: 160880
Availability: 10-12 weeks
Organism: Mouse
Tissue: Bone Marrow
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Stefan Erkeland
Institute: Erasmus Medical Center
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MLL-AF9-miR-139 knock out cell line
- Alternate name: miR-139
- Cancer: Blood cancer
- Cancers detailed: Acute Myeloid Leukaemia (AML)
- Research fields: Cancer
- Parental cell: Lineage negative bone marrow cells isolated from miR139 KO mice
- Organism: Mouse
- Tissue: Bone Marrow
- Donor: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
- Disease: Cancer
- Growth properties: Enhanced Proliferation
- Model: Cancer Model
- Conditional: No
- Description: MIR-139 is a critical tumor surpressor in AML
- Production details: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
- Recommended controls: MIR139 WT, MLL-AF9 cells
Target Details
- Target: MIR139
Handling
- Growth medium: As published in Stavast, C.J., van Zuijen, I., Karkoulia, E. et al. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia 36, 687ÄË?Â?Â700 (2022). https://doi.org/10.1038/s41375-021-01461-5
References
- Stavast et al. 2022. Leukemia. 36(3):687-700. PMID: 34741119.
